tirzepatide pills fda approved Novel, Dual-Targeted Treatment for T2D Is Zepbound, a popular weight loss

Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population-Based Longitudinal Cohort Study

Only 220,000 people will benefit from the drugs in the first three years under current roll-out targets

These hormones bind to receptors throughout your stomach, small intestine, and brain

Monitoring is recommended for the possibility of changes in seizure frequency and / or severity

Trending A Novo Nordisk spokesperson told NOTUS via email that the company has publicly and openly advocated for changes to our health care system to benefit patients, and as part of those efforts, we participate in advocacy and lobbying. Overall, the company spent $2.12 million on lobbying during the fourth quarter of 2025 and $1.24 million during the same period in 2024